Literature DB >> 18283431

Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.

Go Haraguchi1, Hisanori Kosuge, Yasuhiro Maejima, Jun-Ichi Suzuki, Takasuke Imai, Masayuki Yoshida, Mitsuaki Isobe.   

Abstract

OBJECTIVE: To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand. ApoE knockout mice have a high mortality rate due to sepsis because the endotoxin is not cleared. DESIGN AND
SETTING: Prospective study in a university laboratory.
SUBJECTS: We assorted 87 male ApoE knockout mice and 60 wild-type C57/B6 mice randomly into three groups (sepsis, pretreatment, posttreatment).
INTERVENTIONS: Cecal ligation and puncture (CLP) was carried out in the sepsis and treatment groups. Mice were injected with pioglitazone (5 mg/kg per day) on the day before CLP or 6 h after surgery. MEASUREMENTS AND
RESULTS: Both pre- and post-CLP treatment with pioglitazone improved survival of ApoE knockout and wild-type mice. Serum levels of cytokines and chemokines and myeloperoxidase activity in lung and liver were suppressed in the pioglitazone-treated group. Pioglitazone also suppressed monocyte adhesion to vascular endothelium under flow conditions.
CONCLUSIONS: Pioglitazone improved survival of ApoE knockout mice after onset of septic shock through suppression of inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283431     DOI: 10.1007/s00134-008-1024-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  36 in total

1.  Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.

Authors:  Réjane Paumelle; Christophe Blanquart; Olivier Briand; Olivier Barbier; Christian Duhem; Gaëtane Woerly; Frédéric Percevault; Jean-Charles Fruchart; David Dombrowicz; Corine Glineur; Bart Staels
Journal:  Circ Res       Date:  2006-01-05       Impact factor: 17.367

2.  Pioglitazone prevents acute and chronic cardiac allograft rejection.

Authors:  Hisanori Kosuge; Go Haraguchi; Noritaka Koga; Yasuhiro Maejima; Jun-ichi Suzuki; Mitsuaki Isobe
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

3.  Statin treatment after onset of sepsis in a murine model improves survival.

Authors:  Marc W Merx; Elisa A Liehn; Jürgen Graf; Annette van de Sandt; Maren Schaltenbrand; Jürgen Schrader; Peter Hanrath; Christian Weber
Journal:  Circulation       Date:  2005-07-05       Impact factor: 29.690

4.  DTPA Fe(III) decreases cytokines and hypotension but worsens survival with Escherichia coli sepsis in rats.

Authors:  Yan Li; Xuemei Li; Michael Haley; Yvonne Fitz; Eric Gerstenberger; Steven M Banks; Peter Q Eichacker; Xizhong Cui
Journal:  Intensive Care Med       Date:  2006-06-15       Impact factor: 17.440

5.  Apolipoprotein E suppresses the type I inflammatory response in vivo.

Authors:  Kamilah Ali; Melissa Middleton; Ellen Puré; Daniel J Rader
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

6.  Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.

Authors:  M Van Oosten; P C Rensen; E S Van Amersfoort; M Van Eck; A M Van Dam; J J Breve; T Vogel; A Panet; T J Van Berkel; J Kuiper
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

7.  Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.

Authors:  Nikolaus Marx; Jochen Wöhrle; Thorsten Nusser; Daniel Walcher; Angelika Rinker; Vinzenz Hombach; Wolfgang Koenig; Martin Höher
Journal:  Circulation       Date:  2005-10-24       Impact factor: 29.690

8.  Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock.

Authors:  Marika Collin; Maha Abdelrahman; Christoph Thiemermann
Journal:  Eur J Pharmacol       Date:  2004-02-20       Impact factor: 4.432

9.  Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin.

Authors:  Marika Collin; Nimesh S A Patel; Laura Dugo; Christoph Thiemermann
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

10.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  12 in total

1.  Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.

Authors:  Jennifer Kaplan; Marchele Nowell; Ranjit Chima; Basilia Zingarelli
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

Review 2.  Lipid Use and Misuse by the Heart.

Authors:  P Christian Schulze; Konstantinos Drosatos; Ira J Goldberg
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 3.  Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?

Authors:  Konstantinos Drosatos; Anastasios Lymperopoulos; Peter Johannes Kennel; Nina Pollak; P Christian Schulze; Ira J Goldberg
Journal:  Curr Heart Fail Rep       Date:  2015-04

4.  TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.

Authors:  Jerry R Aldridge; Carson E Moseley; David A Boltz; Nicholas J Negovetich; Cory Reynolds; John Franks; Scott A Brown; Peter C Doherty; Robert G Webster; Paul G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-11       Impact factor: 11.205

5.  Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock.

Authors:  Jennifer M Kaplan; Alvin Denenberg; Marie Monaco; Marchele Nowell; Hector Wong; Basilia Zingarelli
Journal:  Intensive Care Med       Date:  2009-09-17       Impact factor: 17.440

Review 6.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

7.  Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury.

Authors:  Aravind T Reddy; Sowmya P Lakshmi; Jennifer M Kleinhenz; Roy L Sutliff; C Michael Hart; Raju C Reddy
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

8.  Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.

Authors:  Ming-Shun Hsieh; Sung-Yuan Hu; Shu-Hui Liao; Chia-Ming Chang; Vivian Chia-Rong Hsieh; Chorng-Kuang How
Journal:  Emerg Med Int       Date:  2021-07-23       Impact factor: 1.112

9.  Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.

Authors:  Carson E Moseley; Robert G Webster; Jerry R Aldridge
Journal:  Influenza Other Respir Viruses       Date:  2010-09       Impact factor: 4.380

10.  Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections.

Authors:  Olivia Majer; Christelle Bourgeois; Florian Zwolanek; Caroline Lassnig; Dontscho Kerjaschki; Matthias Mack; Mathias Müller; Karl Kuchler
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.